Case Study · Acute Coronary Syndrome
How AcceleTrial compressed feasibility timelines for a global ACS trial with an innovative LDL-lowering drug, exceeding both site targets and sponsor expectations.
The Challenge
Identifying and qualifying 60 clinical sites for an Acute Coronary Syndrome study required both volume and speed. Standard feasibility workflows would not meet the sponsor's activation timeline.
The sponsor needed 60 clinical sites with cardiovascular expertise, patient access, and operational readiness for an ACS study involving an innovative LDL-lowering drug.
Communicating with a large number of clinical sites and executing CDAs and Feasibility Questionnaires within a compressed schedule required platform-level automation.
Sites needed to be activated in a timely fashion to accelerate the overall trial timeline. Activation delays at any site created scheduling risk for the study as a whole.
The Solution
Using AcceleTrial, LINEA System identified 65 sites with the cardiovascular trial expertise and patient access required. Turnaround time for feasibility assessments and CDAs was 2 to 3 days, exceeding the sponsor's expectations.
All necessary study documents were collected at 50% the standard timeline through AcceleTrial's automated document workflow. Sites were evaluated against a rigorous set of qualification criteria ensuring each site was operationally ready.
Outcomes
65 cardiovascular sites identified against a sponsor target of 60, all evaluated against protocol-specific criteria.
Feasibility and CDAs completed in 2 to 3 days through AcceleTrial's automated workflow, exceeding sponsor expectations.
All necessary study documents collected at 50% the standard timeline, eliminating the manual coordination bottleneck.
46 LINEA-sourced sites selected and included in the ACS study, with additional sites available in reserve.
Get the Full Story
Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.